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Abstract
The Staphylococcus aureus immune evasion cluster (IEC), located on b-haemolysin-converting bacteriophages (bC-Fs), encodes the
immune-modulating proteins chemotaxis inhibitory protein, staphylococcal complement inhibitor (SCIN), staphylococcal enterotoxin A
and staphylokinase. Its precise role in S. aureus colonization is unclear. We studied the presence of the IEC-carrying bacteriophages in
human and animal S. aureus isolates, using PCR for the gene encoding SCIN (scn). Human isolates were obtained by collecting serial
nasal swabs from 21 persistent carriers. S. aureus strains from 19 (90%) persistent carriers contained an IEC that was present and indis-
tinguishable in 95% of cases at all ﬁve sampling moments over a 3-month period. Of the 77 infectious animal strains included in the
study, only 26 strains (34%) were IEC-positive. Integration of these IEC-positive strains into an ampliﬁed fragment length polymorphism
genotype database showed that 24 of 53 (45%) strains were human-associated and only two of 24 (8%) were ‘true’ animal isolates
(p <0.001). The high prevalence and stability of IEC-carrying bC-Fs in human strains suggested a role for these bC-Fs in human nasal
colonization. To test this hypothesis, 23 volunteers were colonized artiﬁcially with S. aureus strain NCTC 8325-4 with or without the
IEC type B-carrying bC-F13. Intranasal survival was monitored for 28 days after inoculation. The strain harbouring bC-F13 was elimi-
nated signiﬁcantly faster (median 4 days; range 1–14 days) than the strain without bC-F13 (median 14 days; range 2–28 days; p 0.011).
In conclusion, although IEC-carrying bC-Fs are highly prevalent among human colonizing S. aureus strains, they are not essential in the
ﬁrst stages of S. aureus nasal colonization.
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Introduction
Staphylococcus aureus is a human commensal, as well as an
important pathogen that can cause infections ranging from
mild to life-threatening [1]. S. aureus enters the body
through breaches in the skin or mucous membranes, where
it is immediately confronted by the innate immune system as
the ﬁrst line of defence. To counteract innate immunity,
S. aureus expresses a number of immune-modulating pro-
teins. One of the immune-modulating proteins is staphylo-
coccal complement inhibitor (SCIN). It is an efﬁcient
complement inhibitor of the lectin, the classical and the
alternative pathway. SCIN efﬁciently prevents opsonophago-
cytosis and killing of S. aureus by human neutrophils. Fur-
thermore, SCIN prevents generation of C5a and neutrophil
chemotaxis [2,3]. Recently, the gene encoding SCIN (scn)
was found to be part of a so-called ‘immune evasion cluster’
(IEC). Seven IEC variants have been identiﬁed [4]. All IEC
variants carry scn and a different combination of sea, sak and
chp. These genes encode the human-speciﬁc immune modu-
lators staphylococcal enterotoxin A (SEA), staphylokinase
(SAK) and chemotaxis inhibitory protein of S. aureus
(CHIPS). SEA is a well known superantigen [5], and is also
involved in the down-regulation of chemokine receptors of
monocytes [6]. SAK is a bacterial plasminogen activator.
Plasmin formed by the conversion of plasminogen by SAK
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leads to removal of important opsonic molecules, such as
IgG and C3b, by cleaving these molecules. Therefore, SAK
can efﬁciently prevent phagocytosis of staphylococci by
human neutrophils [7]. SAK also inhibits the bactericidal
effect of antimicrobial peptides, the a-defensins [8]. CHIPS
blocks neutrophil chemotaxis by binding the formylated
peptide receptor and the C5a receptor on neutrophils
[4,9,10]. IECs are located on bacteriophages. Bacteriophages
are mobile genetic elements that can be transferred between
strains. The IEC-carrying bacteriophages are incorporated in
the gene encoding b-haemolysin (hlb). Therefore, b-haemoly-
sin is not produced when the IEC-carrying bacteriophage is
present. Consequently, these bacteriophages are called
b-haemolysin-converting bacteriophages (bC-Fs) [4]. It was
shown that 90% of the human clinical S. aureus strains
(isolated from blood, liquor, wounds, continuous ambulatory
peritoneal dialysis ﬂuid, pulmonary ﬂuid, joint and pericardial
ﬂuid) contain an IEC-carrying bC-F; this is an exceptionally
high percentage compared to other mobile elements carrying
virulence factors in human S. aureus strains [4].
Little is known about the prevalence of IEC-carrying bC-
Fs in animal S. aureus strains. It was shown that only 13 of
290 (4.5%) S. aureus strains isolated from cows are IEC-posi-
tive [11]. Other studies showed that b-haemolysin was pro-
duced or hlb was present in 66–92% of S. aureus strains
isolated from cows [12–14]. This indicates that the preva-
lence of IEC-carrying bC-Fs in animal S. aureus isolates is
low in contrast to the prevalence of these bacteriophages in
human infectious S. aureus isolates. Because S. aureus infec-
tions are often endogenous [15,16], we hypothesized that
IEC-encoded immune modulators play a role in colonization
of S. aureus in humans, but not in animals. To test this
hypothesis, we studied the presence and stability of IEC-car-
rying bC-Fs in nasal S. aureus isolates collected from healthy
volunteers. Furthermore, we studied the prevalence of IEC-
carrying bC-Fs in a well described collection of S. aureus ani-
mal isolates. Finally, we performed an artiﬁcial nasal inocula-
tion study in human volunteers in which we compared
survival between S. aureus strain NCTC 8325-4 with and
without IEC-carrying bC-F.
Materials and Methods
Distribution and stability of IEC-carrying bC-Us in human
S. aureus strains
Human S. aureus strains were collected from nasal swab
cultures from 21 healthy, adult persistent carriers who were
positive for S. aureus at ﬁve culture moments over a time
interval of 3 months. S. aureus was cultured quantitatively
and identiﬁed as described previously [17]. For each culture,
up to three colonies of each morphotype (colony morphol-
ogy and haemolysis pattern) were stored at )80C. Single-
locus DNA sequencing of the repeat region of the protein A
gene (spa) was used for comparative genotyping of the
human S. aureus strains [18]. In all strains, scn was ampliﬁed
to determine whether an IEC was present or absent [4].
Furthermore, chp, sak, sea, sep and hlb were ampliﬁed to
determine the IEC type, using previously described PCR
primers and ampliﬁcation conditions [4]. Volunteers provided
their written informed consent and the local Medical Ethics
Committee of the Erasmus MC (Rotterdam, the Nether-
lands) approved the study (MEC-2007-106).
Prevalence of IEC-carrying bC-Us in veterinary S. aureus
strains
Seventy-seven S. aureus strains isolated from different infec-
tion sites in a variety of animal species were used. All strains
were genotyped by ampliﬁed fragment length polymorphism
(AFLP) analysis previously [19]. The AFLP ﬁngerprints of these
animal strains were introduced in an AFLP database compris-
ing data of 829 nonclinical carriage strains isolated from
healthy human individuals [20]. ‘Typical animal strains’ were
deﬁned as strains grouped in AFLP cluster IVa, as described
by van Leeuwen et al. [19]. These strains show no clear AFLP
integration with human carrier strains. ‘Typical human strains’
were deﬁned as animal strains that show considerable inte-
gration with human carrier strains. They grouped in AFLP
clusters I, II and III [19]. Chromosomal DNA was extracted
from the animal strains and the scn gene was ampliﬁed [4].
Artiﬁcial nasal colonization with S. aureus strain NCTC
8325-4 with and without IEC-carrying bC-U
Study population. Twenty-three healthy individuals were
included (eight males and 15 females, median age 29 years,
range 19–58 years). The volunteers provided their written
informed consent and they were notiﬁed of the fact that an
infectious disease physician was on call for the entire study
period. The study protocol was approved by the Medical Eth-
ics Committee of Erasmus MC Rotterdam (MEC-2007-324).
S. aureus strains. C. Wolz provided S. aureus strains NCTC
8325-4 and 8325-4 with bC-F13 [21]. This strain has a
defect in the sigB locus. Thus, although a strain from a natu-
ral carrier would have been preferred, we used NCTC
8325-4 because this strain has been approved for artiﬁcial
colonization, is susceptible to all common antibiotics (e.g.
ﬂucloxacillin and vancomycin) and is devoid of staphylococcal
toxins [22,23]. The volunteers were inoculated with either
wild-type 8325-4 or 8325-4 with bC-F13 containing the IEC
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[4]. We used bC-F13 because it has the most predominant
IEC type (type B) in humans and this type has been
completely sequenced [4,24]. Bacterial growth in tryptic soy
broth was equal for both 8325-4 and 8325-4 with bC-F13
(data not shown).
Artiﬁcial inoculation protocol. The artiﬁcial inoculation proto-
col was as described previously [22,25]. In brief, before inoc-
ulation, the carrier state of the participants was deﬁned on
the basis of two nasal swabs. A volunteer was classiﬁed as a
persistent carrier with two nasal swabs positive and as an
intermittent or noncarrier with one or no swab positive.
Furthermore, a serum sample was drawn for determination
of the C-reactive protein (CRP) level, leukocyte number and
anti-staphylococcal antibody levels. The antibody levels were
determined using a bead-based ﬂow-cytometry technique
(xMAP; Luminex Corp, Austin, TX, USA) as described previ-
ously [26]. After taking the second swab, decolonization
treatment was initiated for all participants (nasal mupirocin
2%; GlaxoSmithKline, Waltham, MA, USA) twice daily for
5 days in combination with once daily washing with chlorh-
exidine-containing soap (SSL Healthcare, London, UK). Five
weeks after the treatment, nostrils were swabbed again to
assess the colonization status and artiﬁcial inoculation was
performed under medical supervision with either wild-type
strain 8325-4 or 8325-4 with bC-F13. Inoculation was per-
formed in a blinded fashion to prevent bias in reading the
microbiological culture results. In both the left and right nos-
tril, 1 · 107 CFU of the same strain were applied. Partici-
pants received hygiene advice and weekly medical checkups.
Follow-up cultures were performed on days 1, 2, 3, 4, 7, 14,
21 and 28 after inoculation. At the end of the study, partici-
pants underwent their last medical examination and serum
samples were drawn to again determine CRP levels, leuko-
cyte numbers and anti-staphylococcal antibody levels. Fur-
thermore, nasal, throat and perineum swabs were collected.
Decolonization therapy was repeated for participants still
carrying the inoculated strain at the end of follow-up.
Nasal swab cultures. Nasal swab cultures were performed as
described previously [25,27]. Both the left and right anterior
nares were swabbed. In short, the swabs were cultured
quantitatively at 37C on Columbia blood agar plates (Bec-
ton-Dickinson BV, Etten-Leur, the Netherlands) to visualize
haemolysis patterns and were submerged in phenol red man-
nitol salt broth. For suspected colonies, a latex agglutination
test (Slidex Staph Plus, bioMe´rieux, Marcy-l’E´toile, France)
was performed. Three colonies of each morphotype were
stored at )80C. For all isolates, a scn and spa PCR was
performed and isolates were typed by pulsed-ﬁeld gel
electrophoresis (PFGE) for identiﬁcation and discrimination
between inoculated and autologous S. aureus strains [4,28].
Statistical analysis
Statistical analyses were performed with SPSS software, ver-
sion 15.0 (SPSS Inc., Chicago, IL, USA). A chi-squared test
was used for comparing proportions or frequencies. After
artiﬁcial colonization, the primary outcome was the survival
time of S. aureus in the nose. The survival time was deﬁned
as the number of days until the ﬁnal positive culture with
the inoculated strain. Kaplan–Meier survival analysis (log-rank
test) was used to compare survival between strain 8325-4
and 8325-4 with bC-F13. Participants still carrying S. aureus
in the nose at the end of follow-up were censored in the
analysis. To compare median number of CFUs and antibody
levels between groups, the Mann–Whitney U-test was used;
p <0.05 was considered statistically signiﬁcant.
Results
Distribution and stability of IEC-carrying bC-Us in human
S. aureus strains
spa-Typing showed that each of the 21 participants carried
the same S. aureus strain at all ﬁve culture moments. Two
of them incidentally carried an additional S. aureus strain.
FIG. 1. Kaplan–Meier survival curves showing proportions of indi-
viduals with culture-positive nasal swab samples after artiﬁcial nasal
inoculation of Staphylococcus aureus strain NCTC 8325-4 with or
without immune evasion cluster (IEC)-carrying bacteriophage.
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Isolates from 19 (90%) persistent carriers contained an
IEC-carrying bC-F, as demonstrated by the presence of scn.
The IEC in strains isolated from each individual was identical
at all ﬁve culture moments in 18 out of 19 (95%) carriers.
The predominant IEC variant was type B (sak, chp and scn),
present in strains from 11 (58%) of 19 volunteers. Variant A
(sea, sak, chp and scn), C (chp and scn), D (sea, sak and scn),
E (sak and scn) and G (sep, sak and scn) were present in
strains isolated from four (21%), two (11%), one (5%), zero
and one (5%) of the nineteen carriers, respectively.
Prevalence of IEC-carrying bC-Us in veterinary S. aureus
strains
Twenty-six of the 77 (33.8%) veterinary isolates were scn-
positive. Strains isolated from animals infected with a ‘typical
animal strain’ were positive for scn in 8.3% (two of 24
strains). By contrast, strains isolated from animals infected
with a ‘typical human strain’ were scn-positive in 24 of 53
(45.3%) isolates (p <0.001). Animals infected with a ‘typical
human strain’ were mostly pet animals in close contact with
humans (cats, dogs, rabbits and horses). Human isolates
(n = 73), sharing similar genetic backgrounds with the iso-
lates obtained from animals infected with a ‘typical human
strain’ (both integrated in almost the same position in the
AFLP dendogram), were scn-positive in 83.6% of strains.
Artiﬁcial nasal colonization with S. aureus strain NCTC
8325-4 with and without IEC-carrying bC-U
Nine volunteers (39%) were classiﬁed as persistent carriers.
Fourteen volunteers were classiﬁed as noncarriers (61%).
Five persistent carriers and seven noncarriers were inocu-
lated with strain 8325-4. The others were inoculated with
strain 8325-4 with IEC-carrying bC-F. According to PFGE
analysis and spa-PCR, in three carriers, including two carriers
who still carried their own strain after mupirocin treatment,
the follow-up cultures after inoculation contained their auto-
logous strain or strains other than 8325-4 only. In none of
these cultures was the inoculated strain detected, suggesting
colonization resistance as a result of the enduring presence
of their own strain. Therefore, these participants (one
inoculated with the phage-positive strain and two with the
phage-negative strain) were excluded from the analysis. For
the remaining 20 participants, S. aureus survival and the num-
ber of CFUs per swab were determined. The Kaplan–Meier
curves in Fig. 1 show the proportion of positive cultures dur-
ing follow-up. The strain containing the IEC-carrying bC-F
was eliminated signiﬁcantly faster (median 4 days; range
1–14 days) than the strain without IEC-carrying bC-F (med-
ian 14 days; range 2–28 days; p 0.011). Antibody measure-
ment showed that this was not a result of higher pre-existing
levels of anti-CHIPS or anti-SCIN IgG in the group of volun-
teers who were inoculated with the IEC-positive strain (med-
ian level of anti-CHIPS IgG, median ﬂuorescence intensity
(MFI) 11604 vs. 12603; anti-SCIN IgG, MFI 8423 vs. 11580;
p >0.05). Although the bacterial count after inoculation
appeared to be higher for the group of participants inoculated
with IEC-containing 8325-4, this was not statistically signiﬁ-
cant (Fig. 2). No signiﬁcant difference in survival and bacterial
count of inoculated S. aureus was shown when noncarriers
were compared with persistent carriers (median survival
4 days for both groups, range 1–28 days and 2–21 days,
respectively), although this might be a result of the small
number of persistent carriers. None of the volunteers experi-
enced adverse effects and all adhered to the study protocol.
At the end of the study, all participants were in good physical
condition. Laboratory values indicated no signs of infection
(CRP <1–8 mg/L, leukocytes 4.5–9.5 · 109/L) and anti-staph-
ylococcal antibody levels showed no increase. All swabs were
negative for the inoculated strain, except for one volunteer
who was treated with mupirocin.
Discussion
It is known that bacteriophages are intrinsically unstable and
that bacterial strains usually tend to loose their bacteriophages
FIG. 2. Bacterial counts after artiﬁcial inoculation. Each dot represents the amount of CFUs in a nasal swab culture of a volunteer collected 1,
2, 3, 4, 7, 14, 21 and 28 days after artiﬁcial nasal inoculation of Staphylococcus aureus strain NCTC 8325-4 with or without immune evasion clus-
ter (IEC)-carrying bacteriophage. Horizontal lines represent the median number of CFUs.
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[29]. In the present study, we demonstrate that S. aureus
strains of 90% of the persistent carriers contained an
IEC-carrying bacteriophage that was present and undistin-
guishable in 95% of cases at all ﬁve culture moments over a
3-month period. This indicates that IEC-carrying bacterio-
phages are highly prevalent and stable over time in human
S. aureus carriage isolates. The predominant IEC variant was
type B, which is the predominant variant in human infectious
isolates as well [4]. The prevalence of IEC-carrying bC-Fs in
the veterinary S. aureus isolates was much lower (33.8%).
However, the percentage of IEC-carrying bC-Fs in strains
isolated from animals infected with human-related S. aureus
strains (45.3%) was higher than in strains isolated from
animals infected with animal-related strains (8.3%). Still, the
percentage of IEC-carrying bC-Fs in strains isolated from
humans was much higher. This indicates that human-related
S. aureus strains in animals appear to lose their bacterio-
phages, whereas S. aureus strains in humans do not. This
apparent advantage of IEC-carrying bC-Fs for human
S. aureus strains, in combination with the high prevalence and
stability, suggested a role for these bacteriophages in human
S. aureus nasal colonization.
Using an artiﬁcial human inoculation study, we were unable
to demonstrate an essential role for IEC-carrying bacterio-
phages in the ﬁrst stages of colonization. The latter is not a
result of the lack of expression of the IEC-encoded proteins.
Inhibition ELISA assays showed that, under in vitro conditions,
both SCIN and CHIPS are produced in S. aureus strain 8325-
4 with IEC-carrying bCF13. The production of SCIN and
CHIPS in this strain is comparable to the production of these
proteins in strains isolated from eight of the persistent carri-
ers included in the present study (data not shown). Perhaps
IEC-carrying bC-Fs play a role in propagation and long-term
(intracellular) survival, rather than adherence, of S. aureus in
the nose. After all, these bacteriophages are present in almost
all S. aureus carrier isolates [4] and, in all individuals tested so
far, signiﬁcant levels of antibodies directed against CHIPS and
SCIN are detected, indicating wide spread in vivo expression
[26,30]. This still does not explain why the phage-positive
strain was cleared signiﬁcantly faster than the phage-negative
strain. A difference in growth rate in vitro was excluded. Fur-
thermore, a difference in nose-picking behaviour between the
volunteers inoculated with the phage-positive strain and
phage-negative strain was excluded by analysing the question-
naires that were ﬁlled in after inoculation. Perhaps the intro-
duction of IEC-carrying bC-Fs altered the regulation and
composition of surface and excreted components of 8325-4
that are normally involved in colonization, and therefore the
clearance of the phage-positive strain is faster. This question
remains to be elucidated.
In conclusion, IEC-carrying bC-Fs are highly prevalent
among S. aureus strains, although these bacteriophages are
not essential in the ﬁrst stages of nasal colonization. Further
research into the role of IEC-carrying bC-Fs in human nasal
colonization is necessary.
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